CCM
ALNY icon

Cadence Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cadence Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-159,255
Closed -$10.7M – 553
2014
Q1 		$10.7M Buy
+159,255
New +$12.3M 0.45% 46

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Cadence Capital Management's ALNY Position: Q2 2014 in Review

Cadence Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2014, closing a stake of 159,255 shares — an estimated $10.7M sold.

Cadence Capital Management first reported a position in ALNY in Q1 2014 and held it in 1 quarter. The position peaked at $10.7M in Q1 2014. 194 funds tracked by Wall St. Rank hold ALNY as of Q2 2014.

  • Cadence Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Cadence Capital Management sold 159,255 Alnylam Pharmaceuticals shares in Q2 2014, an estimated $10.7M.
  • Cadence Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Cadence Capital Management's Alnylam Pharmaceuticals position peaked at $10.7M in Q1 2014.
  • 194 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2014.

Based on Cadence Capital Management's 13F filing for Q2 2014, filed 23 Jul 2014.